Contact this trialFirst, we need to learn more about you.
Mineralocorticoid Receptor Antagonist
Spironolactone for Single Ventricle Heart Condition
Recruiting1 awardPhase 1 & 2
Philadelphia, Pennsylvania
This trial is investigating the effect of Fontan hemodynamics on the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion. A pilot trial of the antifibrotic agent, spironolactone, will be conducted to prevent these consequences and to determine if MRI can discern these differences.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service